Description

  • NCMs strategy is to develop the most advanced PET radiopharmaceutical manufacturing and distribution network. The market for molecular imaging agents in the United States currently exceeds $1.3 billion annually and is expected to grow to over $3 billion by 2020. Most existing manufacturing facilities are outdated, and, due to new FDA regulations, they lack the capacity to meet demands for new compounds while continuing to produce their current line of radiopharmaceuticals. There are approximately 60 new radioactive biomarkers now undergoing clinical trials in the United States. Many of these isotopes will emerge as new products during the next five years. The shortfall in existing production capacity supports our strategy for creating a new PET radiopharmaceutical manufacturing facility. NCM has signed a technology procurement agreement with General Electric (GE) for cyclotron and associated manufacturing technologies. We are introducing patented proprietary technologies from Posi-Med, a first in the PET industry and introducing an innovative technology designed to exceed the newly announced FDA 212 requirements. Introduction of these technologies will establish NCM as a leader in PET manufacturing in the New York area. Early-stage strategic alliances are NCMs core competency and the driver of its long term success. The Companys business strategy relies on its ability to provide a continuous pipeline of novel imaging agents and its relationships with leading pharmaceutical companies and research universities.To supplement its internal product development capabilities, NCM will maintain ongoing sponsored research with world-class scientists. We will expand collaborative relationships with universities and hospitals to identify promising new imaging technologies. NCM will acquire the exclusive licensing rights to discoveries made by university and hospital partners where appropriate.
  • location

    Headquarters:390 Concord Avenue , Bronx, New York, United States

    More
  • Ncm-Usa phone

    Phone Number: +1 212-719-2322

  • Ncm-Usa website

    Website: https://www.ncm-usa.com

  • Ncm-Usa employees

    Employees:21

  • Ncm-Usa revenue

    Revenue:$1 - 10M

  • Ncm-Usa legal name

    Legal Name:Ncm-Usa

  • Ncm-Usa's Social Media

    Ncm-Usa linkedin
  • done Is this data correct?
  • |  NAICS Code: 424210  |

    Show More
Person level website identification

Founder And Owner for Ncm-Usa

Yitzchak Tessler

Founder And Owner

Person level website visitor identification

Sell more in less time!

Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!

View Employees

Yitzchak Tessler

Founder And Owner

Angel Colina

Chief Cyclotron Engineer And Vice President Of Technical Solutions

Refael Tessler

Vice President

Balu Easwaramoorthy

Director Of Drug Development And Cmc

Jim Mcardle

Production Manager

Frequently Asked Questions regarding Ncm-Usa

  • Where are Ncm-Usa's Headquarters?

    Ncm-Usa's Headquarters are in 390 Concord Avenue ,Bronx,New York,United States

  • What is Ncm-Usa's phone number?

    Ncm-Usa's phone number is +1 212-719-2322

  • What is Ncm-Usa's official website?

    Ncm-Usa's official website is https://www.ncm-usa.com

  • What is Ncm-Usa's Revenue?

    Ncm-Usa's revenue is $1 - 10M

  • What is Ncm-Usa's NAICS code?

    Ncm-Usa's NAICS code is 424210

  • How many employees are working in Ncm-Usa

    Ncm-Usa has 21 employees

  • What is Ncm-Usa's Industry?

    Ncm-Usa is in the industry of Pharmaceuticals

  • Who is Ncm-Usa's Founder And Owner?

    Ncm-Usa's Founder And Owner is Yitzchak Tessler

Company Directory